英国制药巨头阿斯利康（AstraZeneca）正与美国竞争对手百时美施贵宝（Bristol Myers Squibb）进行合并谈判[1]。根据报道，该交易估值近400亿美元，合300亿英镑[1]。若交易成功，将创建一个全球第四大的制药集团[1]。
交易消息公布后，阿斯利康股价在伦敦早盘交易中大幅下挫，跌幅超过7%，至116.46英镑的低点[1]。目前阿斯利康市值约196亿英镑，百时美施贵宝市值133亿美元[1]。
谈判已在近几个月内进行，但交易存在不确定性[1]。阿斯利康计划在美国投资500亿美元用于研究和制造，目标到2030年实现销售额80亿美元，较上年的59亿美元增长[1]。百时美施贵宝第二季度收入达129.7亿美元，同比增长5%（不计汇率变动）[1]。
British pharmaceutical giant AstraZeneca is in merger negotiations with American rival Bristol Myers Squibb, according to reporting that has surfaced significant market reaction [1]. The proposed combination would create a pharmaceutical powerhouse valued at approximately $400 billion, positioning the merged entity as the world's fourth-largest pharmaceutical company [1].
News of the discussions triggered an immediate decline in AstraZeneca's share price, which fell more than 7 percent to a low of 116.46 pounds in early London trading [1]. The talks have been ongoing in recent months, though no agreement has been finalized and there remains uncertainty about whether the negotiations will ultimately succeed [1].
The two companies bring substantial existing operations to any potential deal. AstraZeneca holds a market capitalization of approximately 196 billion pounds, while Bristol Myers Squibb is valued at $133 billion [1]. Bristol Myers Squibb reported second-quarter revenue of $129.7 billion, representing 5 percent growth year-over-year when excluding currency fluctuations [1]. AstraZeneca has set ambitious expansion plans, including a $50 billion investment in the United States for research and manufacturing through 2030, with a sales target of $80 billion by that year, up from $59 billion in the prior year [1].